Capivasertib

In this video, Aruna Padmanabhan, MD, discusses therapy combinations for the treatment of PIK3CA-mutated metastatic breast cancer.

Healio spoke with Paolo Tarantino, MD, about FDA approvals in metastatic breast cancer.

An analysis of global conversations involving more than 1,600 health care professionals on social media in November has revealed collective optimism in response to the approval of a new weight-management option for adults with obesity.

The FDA approved capivasertib as part of combination therapy for certain patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer.

Healio spoke with Sara M. Tolaney, MD, MPH, about recent advancements in metastatic breast cancer.

The FDA announced several regulatory actions the past few weeks.

A regimen of fulvestrant plus capivasertib may be effective in a subset of patients with breast cancer, according to results from the CAPItello-291 trial presented at San Antonio Breast Cancer Symposium.

In this video, Sara M. Tolaney, MD, MPH, discusses recent findings examining the use of capivasertib and fulvestrant in patients with aromatase inhibitor-resistant hormone receptor-positive, HER2-negative advanced breast cancer.

SAN ANTONIO — The addition of capivasertib to fulvestrant significantly extended PFS among patients with hormone receptor-positive, HER2-negative breast cancer, according to results presented at San Antonio Breast Cancer Symposium.

The addition of capivasertib to fulvestrant significantly extended PFS among patients with advanced hormone receptor-positive breast cancer, according to topline data released by the agent’s manufacturer.